News and Trends 13 Apr 2023
Aspect and Novo Nordisk working on bioprinted tissue for diabetes and obesity
Aspect Biosystems and Novo Nordisk A/S are set to collaborate on developing bioprinted tissue therapeutics to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s background in stem cell differentiation […]